Chantibody Therapeutics Inc. is a biotech company based in Mountain View, California that focuses on the discovery and development of transformational therapeutics to combat life-threatening diseases, especially cancer. We've developed a proprietary in silico empowered antibody discovery platform as a solid foundation for innovative biologics with diverse formats (mAb, bispecific, multi-specific antibody and fusion protein), and other diverse modalities such as CAR-T, mRNA, and antibody conjugates within our integrated ecosystem. The Chantibody team encompasses industry veterans with proven track records of bringing novel biologics to global clinical trials.

- Set research strategy of developing innovative therapeutics to address patients’ unmet medical needs, build a diversified and differentiated pipeline of biologics with various modalities, two global-first bsAb INDs and multiple (pre-)IND molecules- Lead a group of PhD Scientists and Scientific Researchers in the functional areas of lead discovery and optimization, in vitro validation and in vivo pharmacology, protein expression, purification and characterization, non-clinical toxicology and project management.- Responsible for lead identification, pre-clinical study and eventual IND filing (several in clinical trials now), as well as BD in-licensing scientific evaluation (multiple deals signed), IP, and regulatory affair with FDA (including face-to-face meetings)- VP May 2018 - Feb 2021; SVP Feb 2021 - Jan 2022

- Build and lead a group of 15 PhD level Scientists and Scientific Researchers within Bioanalysis Sciences function, to develop state of the art bioanalytical technologies, methods and strategies for all Genentech Immuno-oncology projects on different platforms (including engineered antibodies, bi-specific antibodies, cancer vaccine).- Enable the characterization of the pharmacokinetic, immunogenic, in vitro biological activities, and circulating protein biomarkers of Genentech biologics development and throughout the product life cycle. - Work closely with Safety, ClinPharm and Biomarker colleagues within leadership and cross-functional teams- Participate In-licensing due diligence and external collaboration- Evaluate and implement new assay platforms for sensitive multiplexed assay using small sample volume- Provided critical assays and data for 4 IND and 3 BLA filing, 2 FDA approvals, and ~ 100 clinical trials

1. Established and led Molecular Immunology department of 9 Scientists and 12 Research Associates.2. Played a critical role in discovery programs (functional screening and human genetics) and new project approval.3, Supported research and clinical programs by protein and antibody generation, ELISA and bioassay, lead selection, disease association, proof of concept and mode of action study, species justification, biomarker identification, target occupancy and engagement assay development and CRO transfer.4. Managed a diverse, motivated and productive group for providing leadership, performance evaluation, and career development, built close working relationship with cross-function and cross-site groups in a global organization, and collaborated with external partners.5. Integrated core molecular and information technologies to ensure tangible deliverables for discovery programs and portfolio projects.- Protein and Cell Technology: provided expression, purification, modification, conjugation, and characterization of proteins and antibodies with multiple formats.- Molecular Biology: applied molecular tools for orphan pairing, reporter gene and phenotypic assays, lenti-viral delivery, and RNAi/CRISPR.- RNA Profiling: executed expression analysis using RNAseq, Nanostring, and qPCR on samples from immune cell atlas, animal models, human biobank, and clinical trials.- Mass Spectrometry: delivered quantitative analysis of protein composition, modification, interaction, and concentration at proteome or individual protein level.- Bioinformatics: developed tools for mid-sized to omics level DNA, RNA and protein datasets, to gain insight and generate hypotheses for target and biomarker candidates.6. Led in-licensing team and drove the evaluation of technology, target and partnering opportunities.7. Participated in Scientific Leadership and Portfolio Management Group for strategy planning, site development, scientific oversight, and pipeline management.

1. Led a cross-functional matrix team on ligand-receptor pairing and biological annotation in B7 families. Identified two novel interactions and studied their immune function (e.g. VSTM3, B7-H6) with potential therapeutic utility in autoimmunity and immuno-oncology. 2. Established an inter-department group on oncology target validation using motif mining and RNAi technology: searched protein database and prioritized the cancer target candidate list based on structure, expression and annotation, implemented shRNA lenti platform, and initiated RNAi screening for potential bispecific antibody targets.3. Supervised 3 Scientists and 4 Research Associates in initiating and executing research plans for drug discovery and validation, and advocated for their career advancement.4. Participated in Cytokine Biology Management Group to evaluate scientific projects and research plans, develop strategies aligned with R&D objectives and company goals, and manage resource needs and pipeline priorities.

1. Discovered three novel ligand-receptor pairings in the IL-10/interferon family (e.g. IL-20, IL-22BP, interferon-lambda), which later out-licensed (to Novo Nordisk and BMS) and developed to clinical programs for psoriasis, rheumatoid arthritis, and Hepatitis C infection.2. Led two cross-disciplinary project teams to study the biological function and therapeutic use of IL-10 family members in psoriasis, presented to pharmaceutical companies as an organization spokesperson, and out-licensed an antibody target to Merck Serono as part of the major research and development alliance agreement.3. Received “Eureka Award” for outstanding scientific breakthrough in 2003.

1. Identified three novel ligand-receptor pairings in the TNF and Class I cytokine families (e.g. TACI, BAFFR, IL-21), which significantly accelerated the annotation of their biological functions and development of drug candidates (out-licensed to BMS, Novo Nordisk, and later moved into phase I and II trials for lupus, rheumatoid arthritis, melanoma, and renal cell carcinoma).2. Generated reporter assay cell lines for functional validation of cytokine receptors, led initiatives for orphan pairing and biological annotation, collaborated with academic partners and produced joint publications. 3. Proposed and led two research projects for studying ligand-receptor interaction, biological function, disease association, and medical hypothesis.

1. Studied the biosynthesis and assembly of human fibrinogen using gene modification and protein expression in mammalian cells, and protein analysis by metabolic labeling and 2-D gel. 2. Cloned thrombin receptor PAR4 and characterized its role in thrombin-stimulated platelet aggregation. 3. Cloned a novel actin-binding protein (ABPL) that binds platelet glycoprotein GPIb-alpha using yeast two-hybrid system.